18F-FDG PET and PET/CT in the evaluation of cancer treatment response.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 19139187.
- Also identified by DOI 10.2967/jnumed.108.054205.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Multimodality imaging, as represented by its greatest exponent, PET/CT, has a firm place in the evaluation of a patient presenting with cancer. With 18F-FDG, PET/CT is rapidly becoming the key investigative tool for the staging and assessment of cancer recurrence. In the last 5 y, PET/CT has also gained widespread acceptance as a key tool used to demonstrate early response to intervention and therapy. In this setting, a major clinical need is being addressed with 18F-FDG PET/CT, because of its inherent ability to demonstrate (before other markers of response) if disease modification has occurred. This review presents available evidence to this effect.
Medical subject headings
- Fluorodeoxyglucose F18
- Neoplasms
- Positron-Emission Tomography
- Tomography, X-Ray Computed